Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-BCC trial
2018-002165-19Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2018
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in basal cell carcinoma (BCC), sponsored by Medical University of Vienna. Primary endpoint: Resectability with primary wound closure. Started Nov 2018; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2018-002165-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002165-19.